Literature DB >> 591256

Recirculation of iopanoic acid after conjugation in the liver.

H I Goldberg, S K Lin, R Thoeni, A A Moss, A Brito.   

Abstract

The purpose of the investigation was to determine if an enterohepatic recirculation occurred for the metabolite of iopanoic acid. The major metabolite of iopanoic acid (Telepaque) in dog bile is the glucuronide conjugate. The identification and quantitation of glucuronide conjugate was accomplished by elemental analysis, paper chromatography, thin layer chromatography, fluorescent excitation analysis, and high pressure liquid chromatography. The stability of iopanoic acid glucuronide in refrigerated dog bile was confirmed. Known amounts of the glucuronide conjugate were instilled into the duodenum of 8 awake adult dogs, and bile collected for 8 hours. Between 19% and 53% (average 31%) of the administered dose was recovered in bile, thereby documenting the presence of an enterohepatic recirculation of conjugated iopanoic acid. The slow rise and plateau of the excretion curve suggests that either the compound is absorbed slowly, or that absorption depends upon deconjugation in the gut. The implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 591256     DOI: 10.1097/00004424-197711000-00013

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  3 in total

1.  Thyroid, renal, and hepatic function tests following cholecystography with high-dose contrast agents.

Authors:  R G Reiner; M J Lawson; J Marshall; T R Read; C G Beng; G T Davies; W G Tucker; A K Grant
Journal:  Dig Dis Sci       Date:  1980-05       Impact factor: 3.199

2.  Concentration and excretion of contrast agents during oral cholecystography as measured by computed tomography in dogs.

Authors:  T B Hunter; G T Fon; R N Berk; M P Capp
Journal:  Gastrointest Radiol       Date:  1981

3.  Self-micellization of gemfibrozil 1-O-beta acyl glucuronide in aqueous solution.

Authors:  David M Shackleford; Richard J Prankerd; Martin J Scanlon; William N Charman
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.